• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical rheumatology. >Prospects for a peptide vaccine for human lupus
【24h】

Prospects for a peptide vaccine for human lupus

机译：人类狼疮多肽疫苗的前景

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Global immunosuppression can control active lupus disease, but the drugs used are toxic and fail to achieve true immunological remission. Targeted downregulation of pathogenic autoimmune cells in lupus should follow such therapies to prevent recurrence and smoldering damage. Lupus patients' immune systems manifest many abnormalities [1] that lead to a pathogenic response to nuclear autoantigens derived from apoptotic cells produced routinely in the body. Normal humans and mice have regulatory mechanisms including Tregs that prevent such an abnormal response [2-4]. A prophylactic vaccine could re-establish the deficiency of Tregs associated with lupus. Even apparently healthy subjects and family members of lupus patients, who might be at risk of developing lupus (as predicted by genetic and other biomarkers), would benefit from such a tolerance vaccine to boost their regulatory mechanisms, which would suppress lupus development in the future. In this very brief editorial, we discuss requisite features of a lupus vaccine and challenges in developing one, using a vaccine candidate as an example with which we have first-hand experience.
机译：整体免疫抑制可以控制活动性狼疮疾病，但所用药物有毒且无法达到真正的免疫学缓解。狼疮病原性自身免疫细胞的靶向下调应遵循此类疗法，以防止复发和阴燃性损害。狼疮患者的免疫系统表现出许多异常[1]，导致对机体常规产生的凋亡细胞衍生的核自身抗原的致病反应。正常人和小鼠具有防止这种异常反应的调节机制，包括Tregs [2-4]。预防性疫苗可以重新建立与狼疮相关的Treg的缺乏。即使是看起来很健康的狼疮患者的受试者和家庭成员，也可能有发展为狼疮的风险（如遗传和其他生物标记所预测的），也将从这种耐受性疫苗中受益，以增强其调节机制，这将在将来抑制狼疮的发展。 。在这篇简短的社论中，我们以狼疮疫苗的第一手经验为例，讨论了狼疮疫苗的必要特征和开发挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号